adjuvanted influenza vaccine + CpG7909

Adjuvanted influenza vaccine + CpG7909 refers to a combination of a standard inactivated split-virus influenza vaccine (such as Fluarix) with the addition of the synthetic immunostimulatory adjuvant CpG 7909. CpG 7909 is a B-class oligodeoxynucleotide containing unmethylated cytosine-phosphate-guanosine (CpG) motifs, which activate Toll-like receptor 9 (TLR9) on human B cells and plasmacytoid dendritic cells. This activation leads to enhanced innate and adaptive immune responses, including increased production of Th1-type cytokines such as IFN-gamma and stronger antigen-specific CD8+ T cell responses[1][4][6][8]. The addition of CpG 7909 has been shown in clinical trials to augment cellular immunity and may allow for dose sparing—achieving similar or improved immunogenicity with lower doses of influenza antigen[1][8]. The primary indication is for prevention of seasonal or pandemic influenza, particularly where enhanced immunogenicity is desired.

Brand names

Fluarix (when used in the referenced studies)

Other names

CpG oligodeoxynucleotide 7909CPG ODN 7909